As healthcare reform issues go, biotechnology is at a level too granular for a presidential campaign. But the expected widespread use of biologics in the not-too-distant future may force the government to address fundamental cost issues in American health-care. Four experts offer their views on what may lie ahead – no matter the outcome of the election.
The healthcare reform proposals offered by Sen. John McCain, the Republican nominee for president, and Sen. Barack Obama, the Democratic nominee, never mention biologics. But biotechnology could serve as the poster child for the challenges one of them will face when presidential attention is turned to America’s healthcare system.
Because of their cost, biologics contribute to a healthcare cost trajectory that most observers consider unsustainable. For many patients, biologics improve the quality of their care, leading to the inevitable question of how much that improvement is worth. Many more people, in essence, have no access to biologic treatment options because of high cost-sharing requirements. Some 46 million more Americans have no insurance, and, thus, have limited access to medical treatments, biologic or otherwise.
Will the next administration sort this all out? How? Biotechnology Healthcare asked four thought leaders to share their perspectives.